Cancer

Health written question – answered on 5th September 2013.

Alert me about debates like this

Photo of Caroline Dinenage Caroline Dinenage Conservative, Gosport

To ask the Secretary of State for Health what steps his Department is taking to improve the provision of gallium PET scans for the treatment of neuroendocrine tumours.

Photo of Anna Soubry Anna Soubry The Parliamentary Under-Secretary of State for Health

Responsibility for determining the overall national approach to improving clinical outcomes from health care services lies with NHS England.

NHS England has advised that University College London Hospital is currently the only centre in the United Kingdom manufacturing 68Ga (gallium) Somatostatin-peptides used in PET scanning, NHS England is aware that there are supply and demand and commercial issues which need to be resolved before it becomes more widely available.

The British Nuclear Medicine Society, the BNMS Molecular Radiotherapy Group, UKINETS (UK and Ireland Neuroendocrine Tumour Society) and the NET Patient Foundation sent a position paper to the then National Clinical Director for Cancer and End of Life Care setting out issues surrounding the availability of Dotatate Radionuclides in the UK, which included the use of Dotatate as an imaging agent with gallium. This information is now with NHS England and the current National Clinical Director for diagnostics.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.